Form 4: Hologic CEO Stephen Macmillan Exercises Options and Sells Shares Under 10b5-1 Plan

Hologic's CEO, Stephen Macmillan, executed stock options and sold shares on July 30, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On July 30, 2024, Stephen Macmillan, the Chairman, President, and CEO of Hologic Inc., exercised stock options to acquire 44,039 shares of common stock at a price of $26.21 per share.
• Simultaneously, Macmillan sold a total of 44,039 shares in multiple transactions at weighted average prices of $80.6, $81.44 and $82.32.
• These transactions were executed under an existing Rule 10b5-1 trading plan adopted on August 30, 2023.
• Following these transactions, Macmillan directly owns 1,157,562 shares of Hologic common stock and indirectly owns 1,146,829 shares through the MacMillan Family Trust.
• The direct holdings include 1,079,673 restricted stock units/performance stock units with deferred settlement.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports transactions under a pre-existing plan, which is a normal course of business. There's no indication of positive or negative implications for the company's outlook.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is generally viewed as a transparent and orderly way for insiders to manage their stock holdings.

Industry Context

Insider transactions are common, and the use of 10b5-1 plans is a standard practice to avoid accusations of trading on non-public information. The market will likely interpret these transactions in the context of Hologic's overall performance and industry trends.

Comparison to Industry Standards

• It is common for CEOs of publicly traded companies, including those in the medical device and diagnostics sector like Hologic, to have compensation packages that include stock options and restricted stock units.
• The use of 10b5-1 trading plans is a standard practice among corporate executives to manage their stock sales in a transparent and compliant manner, similar to practices at companies like Abbott, Danaher, and Siemens Healthineers.
• The reported weighted average sale prices are within a normal range for stock sales by executives, reflecting the current market valuation of Hologic.
• The size of the transaction is not unusual for a CEO of a company with Hologic's market capitalization.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan mitigates concerns about insider trading.
• Employees are unlikely to be directly affected by these transactions.

Key Dates